Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283576 | 1.00 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL52161 | 1.00 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL719518 | 0.98 | SLC7A5 (0.32) | SLC7A5 | |
| SCHEMBL4939776 | 0.98 | SLC7A5 (0.32) | SLC7A5 | |
| SCHEMBL667476 | 0.83 | — | — | |
| SCHEMBL17627358 | 0.83 | — | — | |
| SCHEMBL6156936 | 0.82 | — | — | |
| SCHEMBL27768915 | 0.82 | AKR1B1 (0.30) | — | |
| SCHEMBL28059879 | 0.82 | AKR1B1 (0.30) | — | |
| SCHEMBL7052027 | 0.81 | SLC7A5 (0.38) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576362-B2 | Method for concentrating raw material solution, and system for concentrating raw material solution | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20240050897-A1 | Method for Concentrating Raw Material Solution, and System for Concentrating Raw Material Solution | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-02-15 | — | — | US | disclosed |
| EP-4032601-A1 | METHOD FOR CONCENTRATING RAW MATERIAL SOLUTION, AND SYSTEM FOR CONCENTRATING RAW MATERIAL SOLUTION | Asahi Kasei Kabushiki Kaisha (JP) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022005848-A1 | COMBINATIONS OF CARNOSINE AND ZINC FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | NELSON DEANNA J (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021243359-A1 | TOPICAL COMPOSITIONS AND METHODS | MARY KAY INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021123233-A1 | RETINOL-BASED COMPOSITION | L'OREAL (FR) | 2021-06-24 | — | — | WO | disclosed |
| US-20210093556-A1 | GLUTATHIONE DISULFIDE IN PARENTERAL NUTRITION FOR MAINTAINING OR INCREASING PROTEIN SYNTHESIS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2021-04-01 | — | — | US | disclosed |
| WO-2021016697-A1 | METHOD FOR IDENTIFICATION OF SWINE HAVING ELEVATED MUSCLE CARNOSINE LEVELS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD (CA) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020257438-A1 | A CONTAINER FOR AN AQUEOUS COMPOSITION | SUSU PETS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3710037-A1 | GLUTATHIONE DISULFIDE IN PARENTERAL NUTRITION FOR MAINTAINING OR INCREASING PROTEIN SYNTHESIS | Valorisation-HSJ, Limited Partnership (CA) | 2020-09-23 | — | — | EP | disclosed |
| US-20030027770-A1 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof | KOZHEMYAKIN LEONID A (RU) | 2003-02-06 | — | — | US | disclosed |
| US-6492329-B1 | OXIDIZED GLUTATHIONE | NOVELOS THERAPEUTICS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1122307-A1 | Human carnosinase 2 | SANOFI-SYNTHELABO (FR) | 2001-08-08 | — | — | EP | disclosed |
| US-6251857-B1 | USING OXIDIZED GLUTATHIONE (ALSO KNOWN AS GLUTATHIONE DISULFIDE AND GSSG), DERIVATIVE OR SALT THEREOF; TREATING NEOPLASTIC, INFECTIOUS, HEMATOLOGIC AND IMMUNOLOGIC DISEASES | NOVELOS THERAPEUTICS, INC. | 2001-06-26 | — | — | US | disclosed |
| CN-1207683-A | Potentiators of endogenous production of cytokines and hematopoietic factors and methods of use thereof | M·B·巴拉佐夫斯基 | 1999-02-10 | — | — | CN | disclosed |
| EP-0869809-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | Balazovsky, Mark Borisovich (RU) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997021444-A9 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997021444-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | BALAZOVSKY MARK BORISOVICH (RU) | 1997-06-19 | — | — | WO | disclosed |
| EP-0567564-B1 | Method for diagnosing disorders from biochemical profiles | ESA INC (US) | 1996-10-16 | — | — | EP | disclosed |
| EP-0082015-A1 | Method of forming an image with a photographic cuprous halide material | KONICA CORPORATION (JP) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576362-B2 | Method for concentrating raw material solution, and system for concentrating raw material solution | MAX, OTC, OAT | SLC7A5 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.